Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,385 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Granulocyte-colony stimulating factor Clear all

Conditions: Pediatric, Hodgkin's Disease
Interventions: COPP/ABV, intensive chemo with concurrent growth factor; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 21 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia
Interventions: G-CSF, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, leucovorin calcium, mercaptopurine, methotrexate, prednisone, vincristine sulfate, Allopurinol; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 15 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 50
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 32 more

Conditions: Ependymoma, Recurrent Childhood, Ependymoma
Interventions: Granulocyte Macrophage Colony Stimulation Factor; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Months to 21 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 2
States / cities: Denver, Colorado • Orlando, Florida

Conditions: Melanoma (Skin)
Interventions: MART-1 antigen, filgrastim, flu matrix peptide p58-66, gp100 antigen, recombinant MAGE-3.1 antigen, tyrosinase peptide, in vitro-treated peripheral blood stem cell transplantation; Biological · Procedure
Lead sponsor: Baylor Health Care System; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Ovarian Cancer
Interventions: filgrastim, melphalan, thiotepa, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Lymphoma
Interventions: bleomycin sulfate, filgrastim, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, prednisone, trimethoprim-sulfamethoxazole, vincristine sulfate, radiation therapy, Intrathecal cytarabine; Biological · Drug · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2011
U.S. locations: 85
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more

Conditions: Chemotherapy-induced Neutropenia, Breast Cancer
Interventions: LA-EP2006, Neulasta®; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 10
States / cities: Hot Springs, Arkansas • Jonesboro, Arkansas • Corona, California + 7 more

Conditions: Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions: Falimarev, Inalimarev, Laboratory Biomarker Analysis, Sargramostim; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Chemotherapy-induced Neutropenia
Interventions: Plinabulin, Pegfilgrastim; Drug
Lead sponsor: BeyondSpring Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Redlands, California • Orange City, Florida • Dublin, Georgia + 1 more

Conditions: Melanoma
Interventions: autologous tumor cells plus GM-CSF-in Adjuvant; Biological
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years to 85 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Interventions: filgrastim, gene therapy, lomustine, procarbazine hydrochloride, vincristine sulfate, in vitro-treated peripheral blood stem cell transplantation; Procedure · Biological · Drug
Lead sponsor: Indiana University; Other
Eligibility: 5 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 2
States / cities: Indianapolis, Indiana • Boston, Massachusetts

Conditions: Acute Myelogenous Leukemia, Chronic Myelomonocytic Leukemia
Interventions: DTGM; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma (Skin)
Interventions: aldesleukin, filgrastim, therapeutic tumor infiltrating lymphocytes, cyclophosphamide, fludarabine phosphate, radiation therapy; Biological · Drug · Radiation
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Leukemia, Multiple Myeloma
Interventions: Rituximab, Conditioning chemotherapy, TMS, FLAG, EPOCH-F, Hematopoietic stem cell transplant, Palifermin, Acetaminophen, Diphenhydramine, Prednisone, Epinephrine, IV Saline, ECG, ECHO, MUGA, DEXA, CT chest, PET, MRI, BM aspirate, BM biopsy, Lumbar puncture; Biological · Drug · Procedure + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 2
States / cities: Bethesda, Maryland • Minneapolis, Minnesota

Conditions: Healthy
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hematologic Malignancies
Interventions: Granulocyte Colony Stimulating Factor; Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 22 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Multiple Myeloma
Interventions: Thalidomide; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2007
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Lymphoma
Interventions: filgrastim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, mesna, methotrexate, vincristine sulfate; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Systemic Sclerosis, Systemic Lupus Erythematosus, Dermatomyositis, Juvenile Rheumatoid Arthritis, Autoimmune Diseases
Interventions: Stem Cell Transplantation, CD34 selection; Procedure · Device
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 2 Years to 18 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Lymphoma
Interventions: filgrastim, pegfilgrastim, rituximab, sargramostim, cyclophosphamide, pegylated liposomal doxorubicin hydrochloride, prednisone, vincristine sulfate, immunohistochemistry staining method, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years to 120 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 14
States / cities: La Jolla, California • Los Angeles, California • Miami, Florida + 9 more

Conditions: Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma, Myelodysplastic Syndrome
Interventions: Rituximab, Fludarabine, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Peripheral blood stem cell (PBSC) transplantation, T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells, Prednisone, Allogeneic hematopoietic stem cell transplant (HSCT), Filgrastim, T-Rapa cell Donor Lymphocyte Infusion (DLI); Drug · Procedure · Genetic
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 11 Years to 90 Years
Enrollment: 442 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2017
U.S. locations: 2
States / cities: Bethesda, Maryland • Hackensack, New Jersey

Conditions: Neuroblastoma
Interventions: filgrastim, sargramostim, carboplatin, cisplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, etoposide phosphate, ifosfamide, isotretinoin, melphalan, thiotepa, vincristine sulfate, conventional surgery, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 8
States / cities: Atlanta, Georgia • Boston, Massachusetts • Portland, Oregon + 4 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Thrombocytopenia
Interventions: filgrastim, vitamin E, busulfan, cytarabine, etoposide, fludarabine phosphate, isotretinoin, topotecan hydrochloride, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation; Biological · Dietary Supplement · Drug + 1 more
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 19 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Herceptin, NeuVax vaccine, GM-CSF; Drug
Lead sponsor: George E. Peoples; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 29
States / cities: Beverly Hills, California • Santa Monica, California • Santa Rosa, California + 22 more

Search by objective public record fields.

A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)

Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

Study of the Effect of GM-CSF on Macrophages in Ependymoma

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission

SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors

G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome

D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma

Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma

Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax